Skip to main content

Table 2 Univariate survival analysis

From: Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

Variable

HR

95% CI

P value

Gender

0.75

0.38-1.32

0.24

Age

1.12

1.02-1.14

< 0.001

Performance status

0.98

0.92-1.02

< 0.001

Extent of surgery

0.14

0.10-0.28

< 0.001

MGMT methylation

1.25

1.12-1.32

0.006

TMZ therapy

0.24

0.12-0.41

< 0.001

SLC22A18 promoter methylation

0.64

0.32-1.15

0.13

SLC22A18 protein expression

2.14

1.24-3.72

0.01